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kine gradients, like those created by the ligands for the chemo-Expression of the fractalkine receptor (CX3CR1) in human
kine receptor CCR5, might subsequently guide leukocyte sub-kidney diseases.
sets to specific microenvironments.Background. CX3CL1 (fractalkine) is a membrane bound
chemokine that can function as an adhesion molecule for cells
expressing the receptor CX3CR1. This receptor is involved in
the recruitment of inflammatory cells in a rat model of cres-
The recruitment of leukocytes toward the site of tissuecentic glomerulonephritis, where blockade of CX3CR1 has
injury involves two distinct phases [1]. First, a complexbeen shown to be of benefit. Here we describe the distribution
of CX3CR1 positive cells in a variety of kidney diseases and interaction between inflammatory cells and the endothe-
renal development. lium of blood vessels leads to firm arrest and diapedesis
Methods. A total of 84 formalin-fixed, paraffin-embedded of cells from the circulation [2, 3]. During a second stage,specimens including fetal kidneys (N  12), normal areas of
inflammatory cells migrate deeper into the tissue towardkidneys uninvolved by neoplasia from tumor nephrectomies
(N  4), renal transplant nephrectomies (N  5), renal trans- different microenvironments [4–6]. Chemokines play im-
plant biopsies (N  19), and kidney biopsies from patients portant roles in both stages of this process in inflamma-
with crescentic glomerulonephritis (N  7), membranous ne- tory kidney diseases [6–8].
phropathy (N 7), membranoproliferative glomerulonephritis
The large family of chemokines is divided into the(N  8), focal and segmental glomerulosclerosis (N  10),
four groups of CC, CXC, C and CX3C chemokines [9].collapsing glomerulopathy (N  6), and minimal change dis-
ease (N  6) were studied. Immunohistochemistry was per- The first two of four conserved cysteine residues in the
formed on consecutive tissue sections for CD3 positive T cells, primary amino acid sequence, are either located next to
CD68 positive monocyte/macrophages, CCR5 positive cells each other (CC) or separated by one (CXC) or threeand CX3CR1 positive cells.
amino acids (CX3C). An additional group is missing twoResults. The majority of inflammatory leukocytes infiltrating
of the four cysteine residues (C). Chemokines functionthe kidney expressed CX3CR1. The distribution pattern was
consistent with expression by both T cells and monocytes/ via binding to G-protein coupled seven-transmembrane
macrophages. In contrast to the distribution of CCR5, which spanning receptors, which are named according to the
was expressed on a subset of infiltrating cells predominantly
subgroup of their chemokine ligands (CCRs, CXCRs,localized in the interstitium, CX3CR1 was present on both
XCR, CX3CR1 [6, 9, 10]).interstitial and glomerular infiltrating leukocytes. In developing
kidneys CX3CR1 positive cells formed a small, scattered popu- CX3CL1 (fractalkine) is currently the only chemokine
lation of cells, consistent with the distribution of infiltrating described with three intervening amino acids between
leukocytes. the first two cysteine residues. It is one of two chemo-Conclusions. The high number of CX3CR1-positive in-
kines that is tethered to the cell membrane via a mucinflammatory cells in various disease entities is consistent with
stalk [9, 11, 12]. Localized on the endothelial surface,its having a role in the accumulation of intrarenal inflammatory
cells, but does not provide evidence of specificity of leukocytes CX3CL1 can function both as a chemoattractant and
bearing this receptor for specific types of injury. Other chemo- an adhesion molecule for cells expressing its receptor
CX3CR1 [13, 14]. G protein signaling is necessary for
CX3CR1 to induce migration, but not to support adhe-Key words: chemokines, fractalkine receptor, inflammation, glomeru-
lonephritis, transplant rejection, renal development. sion [14]. Expression of CX3CR1 and migration toward
CX3CL1 has been demonstrated for a wide variety of
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CD3-positive T cells (predominantly CD8 positive cells), (BSA; Sigma Chemicals, St Louis, MO, USA) or 10%
about 79% of CD14 positive monocytes and over 90% non-fat dry milk. After subsequent washing in PBS the
of CD16 positive natural killer cells expressed detectable tissue was incubated with the biotinylated secondary an-
amounts of CX3CR1 [14]. In a model of crescentic glo- tibody (Vector). For signal amplification the ABC-Elite
merulonephritis in Wistar Kyoto rats, CX3CL1 is up- reagent (Vector) was used. 3,3-diaminobenzidine with
regulated and blockade of CX3CR1 by either a broad nickel enhancement, resulting in a black color product,
spectrum chemokine receptor antagonist (vMIP-II) or a served as chromogen. Slides were counterstained with
CX3CR1 blocking antibody demonstrated a strong bene- methyl green, dehydrated and coverslipped.
ficial effect [19, 20]. The distribution of CX3CR1 in hu- A polyclonal rabbit anti-human CX3CR1 antibody
man kidney diseases including renal transplant rejection (AB1891; Chemicon International, Temecula, CA, USA)
is currently unknown. Therefore, we conducted this was used. In Western blots provided by the company,
study on various renal diseases and conditions, which the antibody detects a band of approximately 50 kD,
differ in the localization of infiltrating leukocyte subsets, which can be blocked by preabsorption with the immu-
to describe the expression of CX3CR1 in relation to the nizing peptide. Controls used for this antibody in immu-
inflammatory infiltrates. In addition we compared the nohistochemistry included omission of the primary anti-
expression pattern of CX3CR1 expression with the dis- body, substitution of the primary antibody by irrelevant
tribution pattern of the chemokine receptor CCR5. rabbit IgG, and blockade of the signal by preabsorption
of the primary antibody with the peptide used for immu-
nization (Chemicon Int.). The antibodies MC5 (estab-METHODS
lished and provided by M. Mack) against human CCR5Material
[23], against human CD3 positive T cells (rabbit anti-
A total of 84 formalin-fixed and paraffin-embedded human, A0452; Dako, Carpenteria, CA, USA), and
renal specimens were examined. These consisted of fetal against human CD68 positive monocytes/macrophages
kidneys (N  12), normal areas of tumor nephrectomies (monoclonal mouse anti-human, Clone PG-M1; Dako)
(N  4), renal transplant nephrectomies (N  5), renal have previously been used for immunohistochemistry in
transplant biopsies (N  19), and kidney biopsies from formalin-fixed tissue [22, 24].
patients with crescentic glomerulonephritis (N  7),
membranous nephropathy (N 7), membranoprolifera-
tive glomerulonephritis (N  8), focal and segmental RESULTS
glomerulosclerosis (N  10), collapsing glomerulopathy Expression of CX3CR1 in glomerular diseases
(N  6), and minimal change disease (N  6). The renal
To describe the distribution of CX3CR1 positive cellsbiopsies were from cases studied in the Department of
in relation to infiltrating inflammatory cells we studiedPathology, University of Washington (Seattle, WA,
three groups of tissue samples, which differ by the pre-USA), and were included in this study after the diagnos-
dominant sites of tissue infiltration. Well preserved renaltic workup was completed. Normal areas from tumor
tissue from tumor nephrectomies and biopsies with mini-nephrectomies and transplant rejection nephrectomies
mal change disease was studied, as an example of a non-were collected over the years 1998 to 2001. No clinical
inflammatory disease without significant tubulointersti-data were available for morphological correlations as
tial infiltrates. Glomerular diseases that usually show nothe approval of the University of Washington internal
prominent glomerular inflammatory cell influx, but thatreview board for human subjects prescribes that no pa-
may have variable amounts of tubulointerstitial infil-tient identifiers may be linked to studies involving ne-
trates and fibrosis depending on the disease stage, arephrectomy or biopsy tissue.
represented by membranous nephropathy, focal and seg-
mental glomerulosclerosis and collapsing glomerulopa-Immunohistochemistry
thy. Crescentic glomerulonephritis and mesangioproli-The protocols for immunohistochemistry have pre-
ferative glomerulonephritis (MPGN) are glomerularviously been described in detail [21, 22]. In brief, from
diseases that commonly show prominent glomerulareach specimen serial sections were cut at 4 m. Sections
macrophage influx and, with disease progression, typi-were deparaffinized and rehydrated. Endogenous perox-
cally demonstrate interstitial inflammatory infiltrates andidases were blocked by hydrogen peroxide and antigen
fibrosis. Specimens were stained with hematoxylin andretrieval was performed by microwave treatment in An-
eosin (H&E), and by immunohistochemistry for CD3-tigen Unmasking Solution (Vector, Burlingame, CA,
positive T cells, CD68-positive monocyte/macrophages,USA). Endogenous biotin was blocked using the Avidin/
and the chemokine receptors CX3CR1 and CCR5. Substi-Biotin Blocking Kit (Vector). Primary antibodies were
tution of irrelevant rabbit IgG for the primary detectingapplied for one hour, diluted either in phosphate-buf-
fered saline (PBS) containing 1% bovine serum albumin antisera, and preabsorption of the primary antisera with
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Fig. 1. Establishment of the antibody against human CX3CR1 for immunohistochemistry. Immunohistochemistry on consecutive sections of a
tumor nephrectomy for CX3CR1 (A), preabsorption of CX3CR1 with the peptide used for immunization (B) and irrelevant rabbit IgG (C, original
magnification 400).
the peptide used for immunization, served as negative outnumbered by CD68 positive monocyte/macrophages
and CX3CR1 positive cells. CCR5 positive cells princi-controls for CX3CR1 immunolocalization (Fig. 1).
pally were localized in the tubulointerstitium, consistentIn the group of cases from tumor nephrectomies and
with our previous studies [23]. Although the percentageminimal change disease, only a small number of CD3-
of CCR5-positive infiltrating cells was higher in the inter-positive T cells and CD68-positive monocyte/macro-
stitium as compared to glomeruli, CX3CR1 positive cellsphages could be detected in the interstitium. Small num-
also outnumbered CCR5 positive cells in the interstitiumbers of these cells also could be detected in lumina of
(Fig. 3). In areas of focal T cell infiltrates, there wasperitubular and glomerular capillaries (Fig. 1 and Fig. 2
an overlap in the distribution of CX3CR1 and CCR5,A-C). The distribution of CX3CR1 positive cells mir-
indicating T cells that expressed both chemokine recep-rored the combined distribution of these two infiltrating
tors (Fig. 3 A, D). A population of large, round intratu-cell types. We found no clear evidence for CX3CR1
bular CD68 positive monocyte/macrophages was presentexpression by intrinsic renal cells, with one exception.
in crescentic glomerulonephritis (Fig. 3 E-G). These cellsExpression of CX3CR1 by intrinsic cells was restricted
were almost uniformly positive for CX3CR1, whereasto a single case of allograft rejection in which parietal
they were usually CCR5 negative.epithelial cells in some glomeruli demonstrated positive
immunostaining. CCR5 positive cells were only occa- Expression of CX3CR1 in renal transplants
sionally seen in a similar distribution like CX3CR1 posi-
As in the above description of glomerular diseases,tive cells. The number of CX3CR1 positive cells outnum-
the distribution of CX3CR1 positive cells correlated withbered the number of CCR5 positive cells in normal
that of the two major populations of infiltrating cells, Ttissues as well as in all studied disease entities.
cells and monocyte/macrophages. The number of CX3CR1Biopsies of membranous nephropathy (Fig. 2 D-F),
expressing cells is higher in transplants with acute cellu-
focal and segmental glomerulosclerosis and collapsing
lar and vascular rejection as compared to biopsies with-
glomerulopathy contained variable degrees of interstitial out signs of rejection. A prominent population of CX3CR1
inflammatory cell infiltration, consisting mainly of T cells positive cells was present in the intimal subendothelial
and monocyte/macrophages. The number and distribu- regions of arteries involved in vascular rejection (Fig.
tion of CX3CR1 positive cells correlated well with both 4 A-C). During cellular (interstitial) rejection, inflamma-
types of infiltrating cells. In contrast, CCR5 positive cells tory cells infiltrating the tubular epithelium were gener-
were present in lower numbers than CX3CR1 positive ally CX3CR1 positive (Fig. 4 D, E). Additionally, CX3CR1
cells and the distribution pattern corresponded most to positive cells were present in and around peritubular
that of a subset of infiltrating T cells. capillaries (Fig. 4 E, F). As in glomerular diseases, the
Biopsies of crescentic glomerulonephritis (Fig. 2 G-I) cellular infiltrates were uniformly positive for CX3CR1,
and MPGN (Fig. 2 J-L) demonstrated prominent glomer- whereas only a subset was CCR5 positive.
ular macrophage influx. On consecutive sections glomer-
Expression of CX3CR1 during renal developmentuli demonstrated a similar pattern of CX3CR1 positive
cells as compared to the glomerular macrophage distri- A total of 12 fetal kidneys ranging in age from 58 to
bution (Fig. 2 H-K). The number of glomerular CCR5 122 days were studied. CX3CR1 positive cells formed a
small, scattered population of cells between developingpositive cells was low in both entities and was clearly
Segerer et al: CX3CR1 in human kidney disease 491
Fig. 2. CX3CR1 in well preserved renal tis-
sue and glomerular diseases. Immunohisto-
chemistry for CX3CR1 (A), CD68 positive
monocytes/macrophages (B) and CD3 positive
T cells (C, orig. 400) on a normal area from a
tumor nephrectomy. Scattered CX3CR1 posi-
tive cells are present in the interstitium (arrow-
heads). Immunohistochemistry for CX3CR1
(D), CD68 positive monocytes/macrophages
(E) and CD3 positive T cells (F, orig. 400)
on a biopsy from a patient with membranous
nephropathy. Biopsy from a patient with cres-
centic glomerulonephritis stained with H&E
(G), as well as for CX3CR1 (H) and CD68 pos-
itive monocytes/macrophages (I, orig. 200).
The illustrated glomerulus demonstrated a cel-
lular crescent containing a high number of
monocytes/macrophages and CX3CR1 positive
cells in a similar distribution (arrow). Immuno-
histochemistry for CX3CR1 (J), CD68 positive
monocytes/macrophages (K) and CCR5 posi-
tive cells (L, orig.200) on a biopsy from a pa-
tient with MPGN. A high number of CX3CR1
positive cells were present in the glomeru-
lus (arrow) and additionally in the intersti-
tium (arrowhead). CD68 positive monocytes/
macrophages are the infiltrating cell type in
the glomerulus (arrow), whereas CCR5 posi-
tive cells are mainly found in the interstitium
(arrowhead).
nephrons and in developing glomeruli (Fig. 5). These the type of tissue injury, the involved organ, genetic
cells did not follow typical patterns of cells forming spe- factors of the host and the time course of the insult (acute
cific parts of the developing nephron. Furthermore, these vs. chronic). The discovery of the chemokines, functioning
cells demonstrated no association with the stage of differ- as chemoattractants specific for subsets of inflammatory
entiation of the developing nephron, nor with the age cells, helped explain an apparent discrepancy between
of the kidney. The distribution was consistent with the the previously known chemoattractants that lacked spec-
scattered distribution of CD68 positive cells, although ificities for discrete cell types, and the complexity of
we cannot exclude a CX3CR1 expression by a small inflammatory infiltrates [4, 25]. During recent years it
subset of stromal cells. CCR5 positive cells were very became apparent that subsets of lymphocytes, mono-
rare in developing kidneys and the number of CD68 cytes and dendritic cells express patterns of different
positive cells greatly outnumbered CCR5 positive cells. chemokine receptors according to their stage of matura-
tion and activation [2]. This enables them to follow simul-
DISCUSSION taneous or successive chemotactic gradients in order to
migrate toward specific microenvironments [5, 26].Inflammatory infiltrates are composed of different
subsets of infiltrating leukocytes, influenced in part by Experimental data in animal models suggest an impor-
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Fig. 3. CX3CR1 expression by interstitial in-
filtrates in cases of crescentic glomerulone-
phritis. Immunohistochemistry for CX3CR1
positive cells (A), CD68 positive monocytes/
macrophages (B), CD3 positive T cells (C )
and CCR5 positive cells (D; orig. 400) on
consecutive sections of a biopsy from a patient
with crescentic glomerulonephritis. The right
upper part of the picture shows a focal T cell
infiltrate (C). This area shows an overlapping
positivity for CX3CR1 and CCR5 (A, D).
CX3CR1 shows an additional cell population
in the left upper part of the panel (A). Immu-
nohistochemistry for CX3CR1 positive cells
(E ), CD68 positive monocytes/macrophages
(F ), and CD3 positive T cells (G, orig. 400)
on consecutive sections of a biopsy from a
patient with crescentic glomerulonephritis il-
lustrating intratubular monocytes/macrophages
positive for CD68 and CX3CR1.
tant role of the chemokine-receptor pair of CX3CL1- A recent report localized the expression of CX3CL1
to endothelium of peritubular capillaries but not glomer-CX3CR1 in various inflammatory diseases and make it
an attractive target for therapeutic interventions [19, 20]. uli in humans, although this was demonstrated in a very
small number of vessels [29]. However, a study by Cock-CX3CL1 is up-regulated during crescentic glomerulone-
phritis induced in Wistar-Kyoto rats as well as during well et al demonstrated expression of fractalkine in glo-
meruli, tubular epithelial cells, and peritubular capillar-mouse cardiac allograft rejection [19, 27]. The blockade
of CX3CR1 demonstrated beneficial effects in both ex- ies in settings of acute crescentic glomerulonephritis or
acute renal allograft rejection accompanied by promi-perimental systems. However, in contrast to the data
obtained in rats with crescentic glomerulonephritis, nent parenchymal infiltration by mononuclear leuko-
cytes, but not in normal kidneys or in biopsies of patientsCX3CR1 deficient mice did not demonstrate ameliora-
tion of the disease course in nephrotoxic serum nephritis with non-inflammatory diseases such as minimal change
disease [30]. This is quite complementary to our finding[28]. Differences in the model system and the types of
intervention might account for these results, as specu- of leukocytes bearing the appropriate fractalkine recep-
tor in similar disease settings.lated by the authors [28]. CX3CR1 deficient mice demon-
strated a significant prolongation of heart transplant sur- CX3CR1 is expressed on the two most common groups
of infiltrating cells in inflammatory kidney diseases andvival when treated with low amounts of cyclosporine,
whereas untreated mice demonstrated no differences in renal allograft rejection, namely T cells and monocyte/
macrophages [14]. In the current study we dissected theallograft survival as compared to CX3CR1 expressing
controls [28]. patterns of CX3CR1 positive cells by using disease enti-
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Fig. 4. CX3CR1 expression in renal transplant
rejection. Immunohistochemistry for CX3CR1
positive cells (A), CD68 positive monocytes/
macrophages (B), and CD3 positive T cells
(C, orig. 400) on consecutive sections of a
biopsy from a patient with vascular rejection.
A strong infiltrate of CX3CR1 positive cells
is present in the subendothelial area of the
illustrated artery (arrowhead). (D–F ) Immu-
nohistochemistry for CX3CR1 positive cells
in a biopsy from a patient with cellular (inter-
stitial) allograft rejection with tubulitis (all
orig.1000). (D) CX3CR1 positive cells were
infiltrating the tubular epithelium (arrows).
(E) A CX3CR1 positive infiltrating cell was
adherent to the endothelium of a peritubular
capillary (arrowhead). (F) Infiltrating cells
within the interstitium were seen surrounding
a peritubular capillary, and were uniformly
positive for CX3CR1.
Fig. 5. CX3CR1 expression in renal development. Kidney from a 72-day-old fetus, stained with H&E (A), and for CX3CR1 (B) and CD68 (C,
orig. 400). A scattered population of cells surrounding the illustrated S-shaped body was CX3CR1 positive. Immunohistochemistry for CX3CR1
(D) and CD68 (E, orig. 400) on a kidney from a 103-day-old fetus, showing a small scattered population of cells expressing these markers within
the vascular clefts of developing glomeruli and in the interstitium.
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ties with different distribution of inflammatory cells, while study that demonstrated improved allograft survival in
patients deficient in CCR5 [33].performing concurrent localization of T cells, monocyte/
macrophages, and CCR5 positive cells. The main finding A question that remains unanswered by the present
study concerns the rare appearance of CCR5 positivein this study is that the vast majority of cells infiltrating
glomeruli as well as all parts of the tubulointerstitium in cells in glomeruli in some inflammatory states. Hypo-
thetically this might be due to differences in ligand con-various kidney diseases seem to be capable of CX3CR1
expression. CX3CR1 expression is not limited to certain centration and/or presentation between glomerular and
peritubular endothelium, differences in expression of ad-subsets of infiltrating cells or to localization to specialized
environments (for example, interstitial vs. glomerular) hesion molecules and their ligands on endothelium of
these two compartments, and differences in shear stress.in inflammatory kidney diseases. This is in contrast to our
previous findings on two chemokine receptors, CCR2 Recently, the active movement of T cells away from a
chemokine has been described [34]. Chemokines mightand CCR5, both of which seem to be expressed on spe-
cialized subsets of inflammatory cells and are preferen- not only recruit subpopulations of inflammatory cells to
special microenvironments, but also repulse subsets oftially localized in different renal compartments [22, 23].
In peripheral blood 13% of CD4-positive T cells, 32% cells from entering other compartments.
In summary, our current study as well as correlativeof CD8-positive T cells, 7.8% of monocytes, and 4% of
natural killer cells were CCR5 positive [31]. CCR5 is animal data imply an important role for CX3CL1-
CX3CR1 during renal inflammation. We predict that theexpressed by a large subset of tubulointerstitial inflam-
matory cells, predominantly T cells, but is rarely ex- effect of engagement of this receptor by its endothelial
bound ligand occurs early during the process of leuko-pressed by infiltrating cells in glomeruli [23]. CCR2, on
the other hand, is commonly expressed by leukocytes cyte extravasation. Mice deficient in either CX3CL1 or
CX3CR1 appear to be phenotypically normal, but tem-infiltrating glomeruli and its distribution fits best with
the distribution of monocytes/macrophages [23]. We now porary blockade of this ligand/receptor system has shown
significant beneficial effects in renal injury [35, 36]. Al-present evidence that CX3CR1 is expressed on both T
cells and monocytes/macrophages in renal inflammation. though the compensatory mechanisms in mice deficient
in CX3CL1-CX3CR1 are currently incompletely under-In a study comparing the effects of CX3CR1 and CCR5
blockade, it was found that both approaches showed stood, it raises hopes that therapeutic interventions
aimed at this ligand/receptor system in human renal dis-significant benefits but the antagonism of CX3CR1 was
superior to CCR5 blockade in ameliorating rat crescentic ease might be safe.
glomerulonephritis [19].
Integrating these data into a working model of renal ACKNOWLEDGMENTS
injury, the widespread expression of CX3CR1 at various This work was supported by Grant HL63652 from the National
Institute of Health (USA), by a grant for an O’Brien Kidney Researchsites of inflammation suggests that this chemokine recep-
Center (NIH DK 47659), and from the Else Kro¨ner-Fresenius-Stiftung,tor is not an important mediator of the process by which
Bad Homburg v. d. Ho¨he, Germany.
localization of specific leukocyte subsets to specific mi-
croenvironments during renal inflammation occurs. It Reprint requests to Dr. Charles E. Alpers, Department of Pathology,
University of Washington Medical Center, Box 356100, Seattle, Washing-appears more likely that CX3CR1 functions predomi-
ton 98195, USA.
nantly as an adhesion molecule, functioning in the pro- E-mail: calp@u.washington.edu
cesses of firm adhesion and extravasation of leukocytes
from the circulation. Subsequently, other chemokine REFERENCES
gradients, such as those created by the ligands for CCR5
1. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine
and CCR2 might then function to recruit subsets of leu- receptors in primary, effector, and memory immune responses.
Annu Rev Immunol 18:593–620, 2000kocytes bearing these specific receptors to the target
2. Campbell JJ, Butcher EC: Chemokines in tissue-specific and mi-microenvironments.
croenvironment-specific lymphocyte homing. Curr Opin Immunol
A note of caution has to be raised about the interpreta- 12:336–341, 2000
3. Springer TA: Traffic signals for lymphocyte recirculation and leu-tion of chemokine receptor localization by immunohisto-
kocyte emigration: The multistep paradigm. Cell 76:301–314, 1994chemistry. Chemokine receptors can become desensi-
4. Baggiolini M: Chemokines and leukocyte traffic. Nature 392:565–
tized and internalized upon ligand binding, and therefore 568, 1998
5. Nelson PJ, Krensky AM: Chemokines, chemokine receptors, anddetection of receptor expression may not necessarily cor-
allograft rejection. Immunity 14:377–386, 2001respond with the ability of these cells to migrate toward
6. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine
their appropriate ligands in vivo [32]. This caution not- receptors, and renal disease: From basic science to pathophysio-
logic and therapeutic studies. J Am Soc Nephrol 11:152–176, 2000withstanding, we have previously predicted a role for
7. Rovin BH, Phan LT: Chemotactic factors and renal inflammation.CCR5 in allograft rejection that was extrapolated from
Am J Kidney Dis 31:1065–1084, 1998
the CCR5 pattern detected by immunohistochemistry, 8. Wenzel UO, Abboud HE: Chemokines and renal disease. Am J
Kidney Dis 26:982–994, 1995and this conclusion has recently found support from a
Segerer et al: CX3CR1 in human kidney disease 495
9. Murphy PM, Baggiolini M, Charo IF, et al: International union monocyte chemoattractant protein-1 and its receptor chemokine
receptor 2 in human crescentic glomerulonephritis. J Am Socof pharmacology. XXII. Nomenclature for chemokine receptors.
Nephrol 11:2231–2242, 2000Pharmacol Rev 52:145–176, 2000
23. Segerer S, Mack M, Regele H, et al: Expression of the C-C10. Murphy PM: The molecular biology of leukocyte chemoattractant
chemokine receptor 5 in human kidney diseases. Kidney Int 56:52–receptors. Annu Rev Immunol 12:593–633, 1994
64, 199911. Bazan JF, Bacon KB, Hardiman G, et al: A new class of mem-
24. Segerer S, Regele H, Mack M, et al: The Duffy antigen receptorbrane-bound chemokine with a CX3C motif. Nature 385:640–644,
for chemokines is up-regulated during acute renal transplant rejec-1997
tion and crescentic glomerulonephritis. Kidney Int 58:1546–1556,12. Matloubian M, David A, Engel S, et al: A transmembrane CXC
2000chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol
25. Luster AD: Chemokines–chemotactic cytokines that mediate in-1:298–304, 2000
flammation. N Engl J Med 338:436–445, 199813. Haskell CA, Cleary MD, Charo IF: Molecular uncoupling of
26. Foxman EF, Campbell JJ, Butcher EC: Multistep navigation andfractalkine-mediated cell adhesion and signal transduction. Rapid
the combinatorial control of leukocyte chemotaxis. J Cell Biolflow arrest of CX3CR1-expressing cells is independent of G-pro-
139:1349–1360, 1997tein activation. J Biol Chem 274:10053–10058, 1999
27. Robinson LA, Nataraj C, Thomas DW, et al: A role for fractalkine14. Imai T, Hieshima K, Haskell C, et al: Identification and molecular
and its receptor (CX3CR1) in cardiac allograft rejection. J Immu-characterization of fractalkine receptor CX3CR1, which mediates
nol 165:6067–6072, 2000both leukocyte migration and adhesion. Cell 91:521–530, 1997
28. Haskell CA, Hancock WW, Salant DJ, et al: Targeted deletion15. Fong AM, Robinson LA, Steeber DA, et al: Fractalkine and
of CX(3)CR1 reveals a role for fractalkine in cardiac allograftCX3CR1 mediate a novel mechanism of leukocyte capture, firm
rejection. J Clin Invest 108:679–688, 2001adhesion, and activation under physiologic flow. J Exp Med
29. Furuichi K, Wada T, Iwata Y, et al: Upregulation of fractalkine188:1413–1419, 1998 in human crescentic glomerulonephritis. Nephron 87:314–320, 200116. Foussat A, Coulomb-L’Hermine A, Gosling J, et al: Fractalkine 30. Cockwell P, Chakravorty SJ, Girdlestone J, Savage COS: Frac-receptor expression by T lymphocyte subpopulations and in vivo talkine expression in human renal inflammation. J Pathol 196:85–
production of fractalkine in human. Eur J Immunol 30:87–97, 2000 90, 2002
17. Tong N, Perry SW, Zhang Q, et al: Neuronal fractalkine expres- 31. Mack M, Bruhl H, Gruber R, et al: Predominance of mononuclear
sion in HIV-1 encephalitis: Roles for macrophage recruitment and cells expressing the chemokine receptor CCR5 in synovial effusions
neuroprotection in the central nervous system. J Immunol of patients with different forms of arthritis. Arthritis Rheum 42:981–
164:1333–1339, 2000 988, 1999
18. Harrison JK, Jiang Y, Chen S, et al: Role for neuronally derived 32. Mack M, Luckow B, Nelson PJ, et al: Aminooxypentane-
fractalkine in mediating interactions between neurons and RANTES induces CCR5 internalization but inhibits recycling: A
CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95:10896– novel inhibitory mechanism of HIV infectivity. J Exp Med
10901, 1998 187:1215–1224, 1998
19. Feng L, Chen S, Garcia GE, et al: Prevention of crescentic glomer- 33. Fischereder M, Luckow B, Hocher B, et al: CC chemokine recep-
ulonephritis by immunoneutralization of the fractalkine receptor tor 5 and renal-transplant survival. Lancet 357:1758–1761, 2001
CX3CR1. Kidney Int 56:612–620, 1999 34. Poznansky MC, Olszak IT, Foxall R, et al: Active movement
20. Chen S, Bacon KB, Li L, et al: In vivo inhibition of CC and of T cells away from a chemokine. Nat Med 6:543–548, 2000
CX3C chemokine-induced leukocyte infiltration and attenuation 35. Cook DN, Chen SC, Sullivan LM, et al: Generation and analysis
of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J of mice lacking the chemokine fractalkine. Mol Cell Biol 21:3159–
Exp Med 188:193–198, 1998 3165, 2001
21. Segerer S, Cui Y, Eitner F, et al: Expression of chemokines and 36. Jung S, Aliberti J, Graemmel P, et al: Analysis of fractalkine
chemokine receptors during human renal transplant rejection. Am receptor CX(3)CR1 function by targeted deletion and green fluo-
J Kidney Dis 37:518–531, 2001 rescent protein reporter gene insertion. Mol Cell Biol 20:4106–
4114, 200022. Segerer S, Cui Y, Hudkins KL, et al: Expression of the chemokine
